Eledon Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
19800 MACARTHUR BLVD., IRVINE, CA, 92612
Mailing Address
19800 MACARTHUR BLVD., IRVINE, CA, 92612
Phone
949-238-8090
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 16, 2026 | View on SEC |
| 4 Insider stock transaction report | January 16, 2026 | View on SEC |
| 4 Insider stock transaction report | January 16, 2026 | View on SEC |
| 4 Insider stock transaction report | January 16, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Completed enrollment for the Phase 2 LIGHTHOUSE study for ALS in Q3 2025, with main results expected in Q2 2026.
- Shared positive early results from the Phase 2 OPTIMIZE study for kidney transplant patients in Q4 2025, showing a good safety profile and suggested fewer acute rejections.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.